{"count": 1, "results": [{"_id": "21682834", "pmid": 21682834, "title": "A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients.", "journal": "Diabetes Obes Metab", "authors": ["Borges JL", "Bilezikian JP", "Jones-Leone AR", "Acusta AP", "Ambery PD", "Nino AJ", "Grosse M", "Fitzpatrick LA", "Cobitz AR"], "date": "2011-11-01T00:00:00Z", "doi": "10.1111/j.1463-1326.2011.01461.x", "meta_date_publication": "2011 Nov", "meta_volume": "13", "meta_issue": "11", "meta_pages": "1036-46", "score": 50071.883, "text_hl": "AIM: The purpose of this study was to evaluate if superior glycaemic control could be achieved with @<m>CHEMICAL_rosiglitazone_metformin_combination</m> @CHEMICAL_MESH:C471074 @@@Avandamet@@@  (@CHEMICAL_Rosiglitazone @CHEMICAL_MESH:D000077154 @@@rosiglitazone@@@/@CHEMICAL_Metformin @CHEMICAL_MESH:D008687 @@@metformin@@@/@<m>DISEASE_Intracranial_Arteriovenous_Malformations</m> @DISEASE_MESH:D002538 @@@AVM@@@) compared with @CHEMICAL_Metformin @CHEMICAL_MESH:D008687 @@@metformin@@@ (@CHEMICAL_Metformin @CHEMICAL_MESH:D008687 @@@MET@@@) monotherapy, and if glycaemic effects attained with @<m>DISEASE_Intracranial_Arteriovenous_Malformations</m> @DISEASE_MESH:D002538 @@@AVM@@@ are durable over 18 months of treatment. ", "citations": {"NLM": "Borges JL, Bilezikian JP, Jones-Leone AR, Acusta AP, Ambery PD, Nino AJ, Grosse M, Fitzpatrick LA, Cobitz AR. A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients. Diabetes Obes Metab. 2011 Nov;13(11):1036-46. PMID: 21682834", "BibTeX": "@article{21682834, title={A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients.}, author={Borges JL and Bilezikian JP and Jones-Leone AR and Acusta AP and Ambery PD and Nino AJ and Grosse M and Fitzpatrick LA and Cobitz AR}, journal={Diabetes Obes Metab}, volume={13}, number={11}, pages={1036-46}}"}}]}